论文部分内容阅读
目的观察血管紧张素Ⅱ型受体拮抗剂奥美沙坦酯对高血压患者血压及左心室肥厚的影响。方法采用前瞻性、随机双盲、阳性药物对照研究方法,将54例原发性高血压合并左心室肥厚的患者随机分为奥美沙坦组(治疗组)27例,口服奥美沙坦酯20mg/d,1次/d;缬沙坦组(对照组)27例,口服缬沙坦80mg/d,1次/d,共24周,服药前后分别测量血压,并行心脏超声检查。结果2组治疗前后血压明显下降(P<0.05);左室后壁厚度(PWT)、左心室舒张期室间隔厚度(IVST)、左室重量指数(LVM I)与治疗前相比有明显的统计学意义(P<0.05),2组间比较无差异性(P>0.05)。结论奥美沙坦酯在降低原发性高血压患者血压的同时,可逆转左心室肥厚。
Objective To investigate the effects of olmesartan, an angiotensin Ⅱ receptor antagonist, on blood pressure and left ventricular hypertrophy in patients with essential hypertension. Methods A total of 54 patients with essential hypertension complicated with left ventricular hypertrophy were randomly divided into olmesartan group (treatment group) 27 cases, oral olmesartan medoxomil 20 mg / d, once a day; valsartan group (control group) 27 cases, oral valsartan 80mg / d, 1 time / d, a total of 24 weeks, before and after taking blood pressure were measured, parallel echocardiography. Results Before and after treatment, the blood pressure decreased significantly (P <0.05). The left ventricular posterior wall thickness (PWT), left ventricular diastolic interventricular septum thickness (IVST) and left ventricular mass index (LVM I) Statistical significance (P <0.05), no difference between the two groups (P> 0.05). Conclusion Olmesartan medoxomil can reduce left ventricular hypertrophy while reducing blood pressure in patients with essential hypertension.